__NUXT_JSONP__("/drugs/Nelipepimut-S", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"160212-35-1",chebiId:b,chemicalFormula:b,definition:"A cancer vaccine comprised of a human leukocyte antigen (HLA) A2\u002FA3 restricted HER2\u002Fneu (human epidermal growth factor receptor 2; ErbB2) nonapeptide derived from the extracellular domain of the HER2 protein, with potential immunomodulating and antineoplastic activities. Upon intradermal injection, nelipepimut-S may induce a specific cytotoxic T-lymphocyte (CTL) response against HER2\u002Fneu-expressing tumor cells. HER2\u002Fneu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is overexpressed in various tumor cell types and plays a key role in tumorigenesis.",fdaUniiCode:"7M0A29CD8B",identifier:"C117985",preferredName:a,semanticType:"Immunologic Factor",subclassOf:["C129826","C1663"],synonyms:["E75 Peptide","Human Receptor Tyrosine-Protein Kinase erbB-2 (Proto-Oncogene Neu, Tyrosine Kinase- type Cell Surface Receptor HER2, CD340)-(347-355)-Peptide","L-Leucine, L-lysyl-L-isoleucyl-L-phenylalanylglycyl-L-seryl-L-leucyl-L-alanyl-L- phenylalanyl-","NELIPEPIMUT-S","Nelipepimut S",a,"NeuVax"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FNelipepimut-S",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Nelipepimut-S","","2021-10-30T13:19:31.053Z")));